Publish date:

Global Regenerative Medicine Partnering Deals Report/Directory 2021: Trends, Players And Financials 2014-2021

DUBLIN, Sept. 24, 2021 /PRNewswire/ -- The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2021" report has been added to ResearchAndMarkets.

DUBLIN, Sept. 24, 2021 /PRNewswire/ -- The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2021" report has been added to's offering.

The Global Regenerative Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in regenerative medicine
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for regenerative medicine and stem cells

The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.One of the key highlights of the report is that over 1450 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. Key benefits

  • In-depth understanding of Regenerative Medicine deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
  • Identify most active Regenerative Medicine dealmakers since 2014
  • Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report Scope

Global Regenerative Medicine Partnering Terms and Agreements 2014-2021 is intended to provide the reader with an in-depth understanding and access to Regenerative Medicine trends and structure of deals entered into by leading companies worldwide. Regenerative Medicine Partnering Terms and Agreements includes:

  • Trends in Regenerative Medicine dealmaking in the biopharma industry since 2014
  • Analysis of Regenerative Medicine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to Regenerative Medicine contract documents
  • Leading Regenerative Medicine deals by value since 2014
  • Most active Regenerative Medicine dealmakers since 2014

In Global Regenerative Medicine Partnering Terms and Agreements 2014-2021, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Regenerative Medicine dealmaking2.1. Introduction2.2. Regenerative Medicine partnering over the years2.3. Most active Regenerative Medicine dealmakers2.4. Regenerative Medicine partnering by deal type2.5. Regenerative Medicine partnering by therapy area2.6. Deal terms for Regenerative Medicine partnering2.6.1 Regenerative Medicine partnering headline values2.6.2 Regenerative Medicine deal upfront payments2.6.3 Regenerative Medicine deal milestone payments2.6.4 Regenerative Medicine royalty rates Chapter 3 - Leading Regenerative Medicine deals3.1. Introduction3.2. Top Regenerative Medicine deals by value Chapter 4 - Most active Regenerative Medicine dealmakers4.1. Introduction4.2. Most active Regenerative Medicine dealmakers4.3. Most active Regenerative Medicine partnering company profiles Chapter 5 - Regenerative Medicine contracts dealmaking directory5.1. Introduction5.2. Regenerative Medicine contracts dealmaking directory Chapter 6 - Regenerative Medicine dealmaking by technology type Chapter 7 - Partnering resource center7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmaking

For more information about this report visit

Media Contact:

Research and Markets Laura Wood, Senior Manager    For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets